StockData
Metagenomi Therapeutics, Inc. logo

Metagenomi Therapeutics, Inc. (MGX) stock

MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$0.63−0.05 (-7.21%)

Close on Nov 17, 2026Market cap $23.84MP/E –Yield –

Metagenomi Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

No gross margin figures for Metagenomi Therapeutics

Metagenomi Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Metagenomi Therapeutics figures

See a number that looks wrong?